mRNA vaccine designs for optimal adjuvanticity and delivery

Yuki MochidaSatoshi Uchidaa Department of Advanced Nanomedical Engineering,Medical Research Institute,Tokyo Medical and Dental University (TMDU),Tokyo,Japanb Innovation Center of NanoMedicine (iCONM),Kawasaki Institute of Industrial Promotion,Kawasaki,Japan

DOI: https://doi.org/10.1080/15476286.2024.2333123

2024-03-27

RNA Biology

Abstract:Adjuvanticity and delivery are crucial facets of mRNA vaccine design. In modern mRNA vaccines, adjuvant functions are integrated into mRNA vaccine nanoparticles, allowing the co-delivery of antigen mRNA and adjuvants in a unified, all-in-one formulation. In this formulation, many mRNA vaccines utilize the immunostimulating properties of mRNA and vaccine carrier components, including lipids and polymers, as adjuvants. However, careful design is necessary, as excessive adjuvanticity and activation of improper innate immune signalling can conversely hinder vaccination efficacy and trigger adverse effects. mRNA vaccines also require delivery systems to achieve antigen expression in antigen-presenting cells (APCs) within lymphoid organs. Some vaccines directly target APCs in the lymphoid organs, while others rely on APCs migration to the draining lymph nodes after taking up mRNA vaccines. This review explores the current mechanistic understanding of these processes and the ongoing efforts to improve vaccine safety and efficacy based on this understanding.

biochemistry & molecular biology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the design optimization of mRNA vaccines, especially on how to improve their adjuvanticity and delivery efficiency. Specifically, the paper explores the following key issues:

1. **Optimization of adjuvanticity**:
- Modern mRNA vaccines achieve the co - delivery of antigen - mRNA and adjuvants by integrating adjuvant functions into mRNA nanoparticles. However, excessive adjuvanticity or improper activation of innate immune signaling pathways may reduce the effectiveness of the vaccine and cause adverse reactions. Therefore, how to precisely control the adjuvanticity to activate appropriate signaling pathways and maintain the optimal intensity is an important research direction.

2. **Improvement of the delivery system**:
- mRNA vaccines require an effective delivery system to protect mRNA from enzymatic degradation and deliver it to antigen - presenting cells (APCs) and lymphoid organs. The delivery system should not only ensure the efficient delivery of mRNA but also promote its intracellular translation. In addition, the delivery nanoparticles themselves also have an immunostimulatory effect, which provides new ideas for vaccine design.

3. **Balance between safety and effectiveness**:
- The paper emphasizes that while improving the adjuvanticity of the vaccine, its safety must be ensured. Excessive immune responses will not only affect the effectiveness of the vaccine but may also cause serious side effects. Therefore, how to find a balance between improving the vaccine effectiveness and ensuring safety is an important research objective.

4. **Mechanism understanding and application**:
- By conducting in - depth research on the mechanisms of existing mRNA vaccines and understanding how different components (such as lipids and mRNA) affect the immune response, a theoretical basis can be provided for designing more effective vaccines. For example, the paper discusses the effects of different types of lipid nanoparticles (LNPs) and mRNA modifications on the immune response.

In summary, this paper aims to improve the safety and effectiveness of vaccines by optimizing the adjuvanticity and delivery system of mRNA vaccines, thereby providing guidance for future vaccine design.